1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Date not available
Admin
News Article

Hummingbird Bioscience Initiates HMBD-001 Phase IB Trials in Australia and Partners with Omico

Hummingbird Bioscience has announced a significant step in advancing clinical development by initiating two Phase IB clinical trials in Australia.

The focus of the trials will be on evaluating the activity of HMBD-001, a differentiated HER3-targeting antibody that specifically inhibits HER3 oncogenic signalling. The two patient groups being studied are those with squamous non-small cell lung carcinoma (sqNSCLC) and patients with genetic aberrations in HER3 signalling.

By collaborating with Omico, Hummingbird Bioscience gains access to the PrOSPeCT initiative and network in Australia. Omico's PrOSPeCT initiative will play a crucial role in accelerating the clinical development of HMBD-001 by providing patient referrals to the trials.

Collaborations between Hummingbird Bioscience and Omico represent a step forward in creating a more sustainable and research-led model of healthcare. Together, this partnership has the potential to contribute significantly to advancements in precision medicine and ultimately lead to better outcomes for cancer patients.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!